Last $9.90 USD
Change Today -0.0899 / -0.90%
Volume 2.4K
SCYX On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

scynexis inc (SCYX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $15.00
52 Week Low
08/7/14 - $5.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SCYNEXIS INC (SCYX)

Related News

No related news articles were found.

scynexis inc (SCYX) Related Businessweek News

No Related Businessweek News Found

scynexis inc (SCYX) Details

SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.

90 Employees
Last Reported Date: 05/2/14
Founded in 1999

scynexis inc (SCYX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $250.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $250.2K
Compensation as of Fiscal Year 2013.

scynexis inc (SCYX) Key Developments

SCYNEXIS, Inc. Appoints Steven C. Gilman to its Board of Directors

SCYNEXIS, Inc. announced the appointment of Steven C. Gilman, Ph.D., to its Board of Directors. Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. He currently serves on the board of directors of the Massachusetts Biotechnology Association, Inhibikase, Inc. and the Penn State University Biotechnology Advisory Board.

SCYNEXIS, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 03:05 PM

SCYNEXIS, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 03:05 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Yves Joseph Ribeill, Chief Executive Officer, President and Director.

SCYNEXIS, Inc. Announces Management Changes

SCYNEXIS, Inc. announced that its Board of Directors has appointed Marco Taglietti, M.D., as the Company's Chief Executive Officer, effective April 1, 2015. Dr. Taglietti, a member of the SCYNEXIS Board of Directors, will succeed Yves Ribeill, Ph.D. Dr. Ribeill will remain the Company's President and will continue to serve on the SCYNEXIS Board of Directors. In an unrelated matter, Carole Sable, M.D., the Company's current Chief Medical Officer, is stepping down effective February 20, 2015. Dr. Taglietti was appointed to the SCYNEXIS Board of Directors in December 2014. He previously served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and also as President of the Forest Research Institute until the company was acquired by Actavis, plc. Prior to joining Forest Labs, Dr. Taglietti was Senior Vice President, Head of Global Research and Development at Stiefel Laboratories, Inc. and held various positions with Schering-Plough Corporation where he served as Vice President, Worldwide Clinical Research for Anti-infectives, Oncology, CNS, Endocrinology and Dermatology.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCYX:US $9.90 USD -0.0899

SCYX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCYX.
View Industry Companies

Industry Analysis


Industry Average

Valuation SCYX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCYNEXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at